Mitchell Clark

Dr. Mitchell Clark is an Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine, affiliated with the Division of Gynecologic Oncology. He holds leadership roles including Assistant Program Director of the Minimally Invasive Gynecological Surgery Program and Associate Director of the Center for Precision Diagnosis of Trophoblastic Disease. Dr. Clark completed residency at Yale New Haven Health and fellowship at Princess Margaret Cancer Center, University of Toronto, where he focused on gynecologic oncology and public health research.

Education:

• MD: AUC School of Medicine (2009)
• MPH: University of Massachusetts (2023)
• Fellowship: University of Toronto (2020)

Research Interests: Dr. Clark’s research emphasizes cervical cancer prevention via HPV vaccination strategies, improving ovarian cancer surgical outcomes, and addressing health equity in cancer care through population-level data analysis. He investigates disparities in diagnostic timeliness and cancer staging among racial groups, particularly in uterine and cervical cancers.

Research Trends: His articles focus on clinical trials of novel therapies (e.g., trastuzumab deruxtecan), minimally invasive surgical techniques (ICG fluorescence-guided lymph node mapping), and leveraging healthcare databases to study systemic disparities in gynecologic cancer care.

Awards & Honors:

• NRG Oncology Early Career Investigator (2021)
• AAGL Excellence in Minimally Invasive Gynecology (2017)
• Yale School of Medicine Teaching Award (2017)

Grants & Clinical Roles: Leads studies in ovarian cancer treatment and HPV-related cervical disease. Clinically, he directs the Gynecologic Oncology Program at Stamford Hospital and participates in multidisciplinary teams for hyperthermic intraperitoneal chemotherapy (HIPEC) and hepatic arterial infusion (HAI) therapies.

Labs & Collaborations: Collaborates with teams including Alessandro Santin, Gloria Huang, and Stefania Bellone on translational research. Active in initiatives like the Connecticut Cancer Partnership and DEI committees within the Society of Gynecologic Oncology.